• Mashup Score: 0
    An overview of video-assisted thoracic surgery (VATS) - 7 month(s) ago

    Alan Sihoe, MBBChir, FRCSEd, FCSHK, FHKAM, The University of Hong Kong, Pokfulam, Hong Kong, shares an overview and the benefits of video-assisted thoracic surgery (VATS) for lung cancer management. VATS is a modern minimally invasive surgery that has been beneficial for lung cancer patients who are usually ineligible for surgical therapies. Current goals are to make the surgery less invasive and to ensure enhanced recovery after surgery (ERAS). VATS can also complement pharmacological advances as the time between the procedure and post-operative adjuvant therapy can be significantly reduced. Research has also revealed that circulating tumour (ct)-DNA after VATS may be a useful biomarker for survival, where a lower quantity of ct-DNA after the procedure is associated with better clinical outcomes in adjuvant immunotherapy. Dr Sihoe comments that surgeons are continuously finding useful roles for VATS in lung cancer management. This interview took place at the 2023 World Conference on L

    Source: www.vjoncology.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      🎥@ASihoe of @HKUniversity highlights the advantages of Video-Assisted Thoracic Surgery (VATS) in #lungcancer management, promoting less invasiveness and faster recovery: ➡️https://t.co/3SRWS83Dnj⬅️ #WCLC23 #LCSM #SurgOnc

  • Mashup Score: 0
    The case for open radical cystectomy over robotic surgery in bladder cancer - 8 month(s) ago

    Dickon Hayne, MBBS, MD, FRCS, FRACS, The University of Western Australia, Perth, Australia, discusses the current advantages of open radical cystectomy in bladder cancer. Whilst robotic cystectomy may result in less bleeding and shorter hospital stays, robotic surgery fails to completely replicate open radical cystectomy. More ureteral strictures are observed in robotic cystectomies, which adversely affects patients. Dr Hayne additionally highlights the need for cystectomies to be performed in high-volume centres for optimal results. This interview took place at the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group annual scientific meeting in Melbourne, Australia. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjoncology.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      🎥Prof. Dickon Hayne (@uwanews) discusses open radical cystectomy's advantages over robotic surgery in bladder cancer treatment: ➡️https://t.co/svf9SU0IMc⬅️ #ANZUP23 #Blcsm #SurgOnc

  • Mashup Score: 10
    Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer - 8 month(s) ago

    PURPOSE Bladder-sparing trimodal therapy (TMT) is an alternative to radical cystectomy (RC) according to international guidelines. However, there are limited data to guide management of nonmetastatic clinically node-positive bladder cancer (cN+ M0 BCa). We performed a multicenter retrospective analysis of survival outcomes in node-positive patients to inform practice. METHODS Data from patients diagnosed with cN+ M0 BCa were collected from participating UK Oncology centers offering both TMT and RC. Overall survival (OS) and progression-free survival (PFS) outcomes were collected with details of treatment and clinical factors. RESULTS A total of 287 patients with cN+ M0 BCa were included in the survival analysis. Median OS across all patients was 1.55 years (95% CI, 1.35 to 1.82 years). Receiving radical treatments was associated with improved OS (hazard ratio [HR], 0.32; 95% CI, 0.23 to 0.44; P < .001) compared with receiving palliative treatment. Radically treated patients (n = 163) r

    Source: ascopubs.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCO_pubs
      ASCO_pubs

      🤔 Can the bladder be spared? Comparing survival outcomes after surgery vs radical radiotherapy for cN+ #BladderCancer ➡️ https://t.co/nXnNce1ePj #blcsm #radonc #surgonc @swinton_martin @achoud72 https://t.co/Y0srRkVCIh

  • Mashup Score: 1
    Surgeon Quality and Patient Survival After Resection for Non–Small-Cell Lung Cancer - 8 month(s) ago

    PURPOSE The quality and outcomes of curative-intent lung cancer surgery vary in populations. Surgeons are key drivers of surgical quality. We examined the association between surgeon-level intermediate outcomes differences, patient survival differences, and potential mitigation by processes of care. PATIENTS AND METHODS Using a baseline population-based surgical resection cohort, we derived surgeon-level cut points for rates of positive margins, nonexamination of lymph nodes, nonexamination of mediastinal lymph nodes, and wedge resections. Applying the baseline cut points to a subsequent cohort from the same population-based data set, we assign surgeons into three performance categories in reference to each metric: 1 (<25th percentile), 2 (25th-75th percentile), and 3 (>75th percentile). The sum of performance scores created three surgeon quality tiers: 1 (4-6, low), 2 (7-9, intermediate), and 3 (10-12, high). We used chi-squared, Wilcoxon-Mann-Whitney, and Kruskal-Wallis tests to comp

    Source: ascopubs.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCO_pubs
      ASCO_pubs

      📽️ Check out a new #JCO video abstract: @ROsarogiagbon et al. wrote an article on surgeon quality and patient survival after resection for #NSCLC 👉 https://t.co/dRg0sc2z1o #LungCancer #LCSM #surgonc

Load More